Update on SMC remobilisation

2 October 2020 - SMC business recovery following the early stages of the COVID-19 pandemic continues to progress well. ...

Read more →

Scottish Medicines Consortium accepts nasal spray for depression previously rejected by NICE

8 September 2020 - Esketamine nasal spray can now be provided on the NHS in Scotland for adults with major depressive ...

Read more →

SMC accepts three new health technologies for interim use

7 September 2020 - In what appears to be a new process, the SMC has accepted three new technologies for ...

Read more →

Four new medicines accepted by SMC through an expedited approach

7 September 2020 - Medicines accepted to minimise delay in patient access following the early phase of the COVID-19 pandemic. ...

Read more →

SMC recommends Merck's Keytruda for another two indications

7 September 2020 - Pembrolizumab (Keytruda) has been accepted for the treatment of patients with head and neck squamous cell carcinoma ...

Read more →

SMC accepts Spravato (esketamine) nasal spray for use in adults with treatment-resistant major depressive disorder in Scotland

7 September 2020 - SMC acceptance comes less than a week after second rejection by NICE. ...

Read more →

SMC - September 2020 decisions

7 September 2020 - The SMC has today published advice accepting fourteen new medicines. ...

Read more →

SMC - August 2020 decisions

10 August 2020 - The Scottish Medicines Consortium has today published advice accepting neratinib (Nerlynx) for the treatment of breast ...

Read more →

SMC response to COVID-19

22 May 2020 - To prioritise and support the capacity of health and social care services, Healthcare Improvement Scotland and the ...

Read more →

SMC - April 2020 decisions

13 April 2020 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today published ...

Read more →

SMC - March 2020 decisions

9 March 2020 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

SMC approves first two ‘ultra-orphan’ pathway meds

11 February 2020 - The Scottish Medicines Consortium has released its February guidance, advising six new medicines to NHS Scotland. ...

Read more →

SMC - February 2020 decisions

10 February 2020 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...

Read more →

SMC - January 2020 decisions

13 January 2020 - Medicines which can be used to treat prostate cancer, primary progressive multiple sclerosis, a rare form ...

Read more →

NICE and the SMC have published recommendations on Shionogi’s Mulpleo (lusutrombopag), approving its use for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures

12 December 2019 - Mulpleo (lusutrombopag) is the first licensed treatment to be made available through the National Health Service ...

Read more →